<DOC>
	<DOCNO>NCT00527228</DOCNO>
	<brief_summary>The present study design assess natural history one year pre-phase trial evaluate therapeutic efficacy side effect deflazacort LGMD2B/MM patient placebo-controlled trial . Furthermore , long-term development disease naturalistic condition document 2-year follow-up end double-blind treatment phase .</brief_summary>
	<brief_title>Deflazacort Dysferlinopathies</brief_title>
	<detailed_description>Limb girdle muscular dystrophy ( LGMDs ) genetically heterogeneous group disorder encompass various genetically define subtypes ( LGMD 2A-2H ) . Therapeutic trial address disease entity separately assess effectiveness medical treatment . A placebo-controlled trial patient dysferlinopathy may reveal insight natural course disease show therapeutic option homogeneous group patient . So far , steroid drug show efficacy muscular dystrophy , mainly Duchenne muscular dystrophy ( DMD ) . Both dystrophin dysferlin attach sarcolemma deficiency protein cause sarcolemmal defect ; therefore , membrane-stabilizing steroid effect may beneficial DMD LGMD2B/ Myoshi myopathy ( MM ) . Furthermore , marked inflammation muscle biopsy many LGMD2B patient . Therefore , anti-inflammatory effect steroid may improve muscle function LGMD2B/MM . In trial , effect deflazacort patient dysferlinopathy ( LGMD2B/MM ) strength daily-life activity address . The present study design assess natural history evaluate therapeutic efficacy side effect deflazacort / placebo LGMD2B/MM patient . Although major therapeutic breakthrough achieve curative treatment modality yet applicable , life expectancy quality life dysferlinopathy patient could remarkably improve establish drug therapy , capable delay dystrophic process improve muscle strength function . Therefore , result study warrant may influence guideline steroid treatment dysferlinopathies . Furthermore , assessment natural history disease provide new insight clinical understanding dysferlinopathies .</detailed_description>
	<mesh_term>Muscular Dystrophies , Limb-Girdle</mesh_term>
	<mesh_term>Deflazacort</mesh_term>
	<criteria>Clinically , histologically , immunohistochemically genetically define muscular dystrophy dysferlindeficiency ( LGMD2B/MM ) . Patients fulfill clinical , morphological , immunohistochemical immunoblot criterion LGMD 2B definite mutation dysferlin gene . There limitation age study inclusion . Patients confine bed wheelchair . Patients neurologic internistic disease patient former current steroid treatment include . Exclusion criterion trial withdrawal inform consent lack compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Muscular dystrophy</keyword>
	<keyword>therapy</keyword>
	<keyword>steroid</keyword>
	<keyword>deflazacort</keyword>
	<keyword>dysferlinopathy</keyword>
	<keyword>LGMD</keyword>
	<keyword>MM</keyword>
</DOC>